Empowering people affected by penile cancer: towards a model for supportive self-management

Empowering people affected by penile cancer: towards a model for supportive self-management

Introduction

Penile cancer is a rare malignancy that can have an aggressive natural history, and often requires highly morbid surgical interventions [1]. Penile cancer has varying incidence rates globally. In high-income countries, the standardised incidence has been reported at 0.94/100,000 in Europe and 0.5/100,000 in the USA [2]. In contrast, incidence rates in low- to middle-income countries have been reported as high as 0.7–3.0/100,000 in India, 8.3/100,000 in Brazil, and even higher in other parts such as Africa [3, 4]. Due to the rarity of the disease and the variability of global distribution, the options for clinical management and access to supportive cancer care are inequitable and fragmented at the individual (each patient), meso (health system), and macro (policy-making) level [5,6,7]. Moreover, recent evidence demonstrates guideline knowledge is suboptimal with inconsistent clinician adherence [8, 9] leading to unwanted variations in patient outcomes and subsequent requirements for supportive care.

Supportive care is a person-centred approach to the delivery of cancer services for those affected by cancer to meet their emotional, physical, social, spiritual, and informational needs during diagnosis, treatment, or follow-up phases of care. These needs include issues of health promotion, preventive care, survivorship, palliation, and bereavement care [5, 10]. A diagnosis of penile cancer and its associated highly morbid treatments presents numerous challenges that have been largely unmet in routine service delivery as evidenced by a recent systematic review [5]. Penile cancer causes significant distress due to physical issues (fatigue, genital pain, urinary and sexual dysfunction, scars, stenosis and bleeding, lymphoedema, sleep problems, mobility limitations, reduced strength, frequent infections, and impaired wound healing) [11,12,13,14,15], and psychosocial morbidity (anxiety, depression, suicidal ideation, sadness, lowered self-esteem, post-traumatic stress disorder, altered body image and masculine identity, isolation, fear of death and dying) [13, 16, 17]. Men living with penile cancer receive very limited, if any, supported self-management interventions or pre-and/or rehabilitative models of care [5, 18, 19]. This discussion article aims to provide a new direction and model for delivering person-centred care to optimize supported self-management for men affected by penile cancer [5, 6].

Supported self-management

It is necessary to distinguish the concepts of self-care, self-management, and supported self-management in order to facilitate the further development of coherent and consistent research, policy, and practice recommendations and address existing care shortcomings among men with penile cancer [5, 6]. The World Health Organization defines self-care as “the activities individuals, families, and communities undertake with the intention of enhancing health, preventing disease, limiting illness, and restoring health” [20]. This description reflects that self-care skills and knowledge stem from lay experience and suggests that self-care is a part of daily living for all. Whereas self-management refers to an individual’s ability to manage the physical, psychological, and social consequences, symptoms, treatment regimes, and lifestyle changes inherent in living with a long-term condition, such as cancer [21, 22]. The concept of self-management is associated with the management of long-term conditions by patients at home unsupervised by healthcare professionals [23]. On the other hand, supported self-management is a patient-centered collaborative approach to empowerment, patient activation, and education that extends the role of healthcare professionals beyond the delivery of information and traditional patient education [22, 24, 25].

In supported self-management, healthcare professionals actively collaborate with patients to facilitate increased levels of confidence and self-efficacy and engage in shared decision-making to deliver improved self-management and better quality-of-life outcomes. Supported self-management provides individualised patient support to enhance self-management behaviours, improve problem-solving capabilities, while promoting an active collaboration with the cancer healthcare team [26]. The supported self-management model of care has been highlighted as a critical component to ensure patient well-being, particularly in long-term conditions, like cancer, and the increased use of non-pharmacological approaches to symptom management [27]. See Table 1 for characteristics of self-care, self-management, and supported self-management in cancer.

Table 1 Characteristics of self-care, self-management, and supported self-management in cancer.
Full size table

Supported self-management in penile cancer

The multifaceted symptoms and effects associated with penile cancer present significant management challenges to the patient and healthcare professional, across the entire cancer care continuum, from diagnosis, to survivorship, and palliative and end-of-life care [5, 17]. Urinary and sexual dysfunction, along with other psychosocial and physical issues, can significantly impact the quality of life for people affected by penile cancer. Clinical management approaches, such as organ-preserving surgery where feasible [28, 29], may help improve cosmetic outcomes and sexual function. Long-term management of the psychosocial and physical symptoms associated with penile cancer often involves addressing behavioral risk factors (e.g., depression, anxiety, body image concerns, urinary dysfunction, fatigue) through undertaking self-management behaviours (e.g., undertaking specific exercises, engaging in cognitive therapy techniques). Examples of self-management strategies for penile cancer-related symptoms are presented in Table 2.

Table 2 Examples of supported self-management in penile cancer.
Full size table

Patient engagement in self-management behaviours and strategies can be complex, as it can require individuals to recognize, track, self-monitor, self-report, and apply problem-solving skills for their penile cancer-related symptoms alongside any other comorbid conditions; tasks with which most patients are not familiar. For example, patients undertaking intermittent self-dilation for urethral stricture disease following radiotherapy or performing self-examination of penis and inguinal lymph nodes to look for recurrence of cancer in the setting of penile sparing therapy. Furthermore, factors such as the severity of symptoms, socioeconomic status, mental health, cognitive ability, age, physical performance, and other situational influences can complicate the capabilities of patients to self-manage. The severity of treatment options and associated consequences of urinary and sexual dysfunction, coupled with psychological effects and altered perceptions of masculinity, underscores the need for anticipatory and timely supported self-management models of care delivery to help patients navigate the complexities associated with the self-management of penile cancer side effects [6, 13, 17]. To the best of our knowledge, there have been no reported studies [5, 6, 19] in supported self-management interventions in penile cancer. However, in other genitourinary cancer patient groups who experience issues such as urinary and sexual dysfunction (which are common to penile cancer), a nurse-led model of supported self-management, safely embedded in the Multidisciplinary Team (MDT), was found to improve supportive care and patients’ ability to self-manage [30, 31].

Effective supported self-management requires a multidisciplinary approach tailored to individual needs (Fig. 1). In fact, penile cancer provides an exceptionally compelling case for supported self-management programs not just for centralised referral cancer centres [32,33,34] but equity in quality care for all individuals. The multidisciplinary team’s involvement should be tailored to the individual across the cancer care continuum [35] which includes surgeons, oncologists, radiation oncologists, pathologists, radiologists, specialist nurses, physiotherapists, exercise physiologists, health psychologists, social workers, radiation therapists, dieticians, lymphedema practitioners, palliative care practitioners, general practitioners, and relationship therapists who are actively engaged with the model of supported self-management. Supported self-management in other cancer types has been shown to increase emotional and physical functioning, improve quality of life and survival, reduce healthcare costs and usage, and reduce symptom burden [36,37,38]. People with penile cancer are particularly vulnerable and as healthcare professionals aspire to greater personalized care and treatment it is essential to enable those affected by penile cancer to be active contributors to the self-management of their disease and health [1].

Fig. 1
Empowering people affected by penile cancer: towards a model for supportive self-management

Penile Cancer Supported Self-Management.

Full size image

Outlook and future

First, there is a need to explore and clearly define the self-management behaviors and factors associated with improved symptom management for patients with penile cancer. Additionally, definition of symptom clusters—groups of related symptoms that occur together—can provide insights into how self-management strategies might address multiple symptoms simultaneously. This knowledge in turn may allow efficiencies in the design of interventional strategies and help tailor self-management interventions to enhance overall symptom control and quality of life for men with penile cancer. While the delivery of supported self-management is highly attainable in centralised penile cancer services, for example, in North America, Europe and Australia, it may not be possible in all parts of the world particularly in low- and middle-income countries where the development of cancer nursing and cancer services requires significant support from the international cancer partners, as evidenced by recent research [39]. Creating meaningful change in penile cancer management in such countries will require policymakers, government officials, and international cancer organizations to continue to work together to support cancer control in light of the current and projected limited resources and barriers in cancer diagnosis and management [40, 41].

Conclusion

Current knowledge is limited regarding the implementation, effectiveness, and impact on patient outcomes of supported self-management programs in penile cancer. Supported self-management has been shown in other settings to be a powerful lever to achieving personalized high-quality care by facilitating patients’ skills development to attain effective self-management capabilities [42]. This approach requires a refocus and change of healthcare professional activity to create a distinct collaborative partnership with patients to enable patient empowerment, activation, and education in self-management. Healthcare professionals and healthcare systems must adapt to better meet the needs of people with this rare cancer. Champions in organisations across the globe, particularly in centralised referral cancer centres are needed to lead the way in high-quality and consistent self-management support to improve the lives of men with penile cancer.

Related Articles

Energy metabolism in health and diseases

Energy metabolism is indispensable for sustaining physiological functions in living organisms and assumes a pivotal role across physiological and pathological conditions. This review provides an extensive overview of advancements in energy metabolism research, elucidating critical pathways such as glycolysis, oxidative phosphorylation, fatty acid metabolism, and amino acid metabolism, along with their intricate regulatory mechanisms. The homeostatic balance of these processes is crucial; however, in pathological states such as neurodegenerative diseases, autoimmune disorders, and cancer, extensive metabolic reprogramming occurs, resulting in impaired glucose metabolism and mitochondrial dysfunction, which accelerate disease progression. Recent investigations into key regulatory pathways, including mechanistic target of rapamycin, sirtuins, and adenosine monophosphate-activated protein kinase, have considerably deepened our understanding of metabolic dysregulation and opened new avenues for therapeutic innovation. Emerging technologies, such as fluorescent probes, nano-biomaterials, and metabolomic analyses, promise substantial improvements in diagnostic precision. This review critically examines recent advancements and ongoing challenges in metabolism research, emphasizing its potential for precision diagnostics and personalized therapeutic interventions. Future studies should prioritize unraveling the regulatory mechanisms of energy metabolism and the dynamics of intercellular energy interactions. Integrating cutting-edge gene-editing technologies and multi-omics approaches, the development of multi-target pharmaceuticals in synergy with existing therapies such as immunotherapy and dietary interventions could enhance therapeutic efficacy. Personalized metabolic analysis is indispensable for crafting tailored treatment protocols, ultimately providing more accurate medical solutions for patients. This review aims to deepen the understanding and improve the application of energy metabolism to drive innovative diagnostic and therapeutic strategies.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

Macrophages are immune cells belonging to the mononuclear phagocyte system. They play crucial roles in immune defense, surveillance, and homeostasis. This review systematically discusses the types of hematopoietic progenitors that give rise to macrophages, including primitive hematopoietic progenitors, erythro-myeloid progenitors, and hematopoietic stem cells. These progenitors have distinct genetic backgrounds and developmental processes. Accordingly, macrophages exhibit complex and diverse functions in the body, including phagocytosis and clearance of cellular debris, antigen presentation, and immune response, regulation of inflammation and cytokine production, tissue remodeling and repair, and multi-level regulatory signaling pathways/crosstalk involved in homeostasis and physiology. Besides, tumor-associated macrophages are a key component of the TME, exhibiting both anti-tumor and pro-tumor properties. Furthermore, the functional status of macrophages is closely linked to the development of various diseases, including cancer, autoimmune disorders, cardiovascular disease, neurodegenerative diseases, metabolic conditions, and trauma. Targeting macrophages has emerged as a promising therapeutic strategy in these contexts. Clinical trials of macrophage-based targeted drugs, macrophage-based immunotherapies, and nanoparticle-based therapy were comprehensively summarized. Potential challenges and future directions in targeting macrophages have also been discussed. Overall, our review highlights the significance of this versatile immune cell in human health and disease, which is expected to inform future research and clinical practice.

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.

Probabilistic machine learning for battery health diagnostics and prognostics—review and perspectives

Diagnosing lithium-ion battery health and predicting future degradation is essential for driving design improvements in the laboratory and ensuring safe and reliable operation over a product’s expected lifetime. However, accurate battery health diagnostics and prognostics is challenging due to the unavoidable influence of cell-to-cell manufacturing variability and time-varying operating circumstances experienced in the field. Machine learning approaches informed by simulation, experiment, and field data show enormous promise to predict the evolution of battery health with use; however, until recently, the research community has focused on deterministic modeling methods, largely ignoring the cell-to-cell performance and aging variability inherent to all batteries. To truly make informed decisions regarding battery design in the lab or control strategies for the field, it is critical to characterize the uncertainty in a model’s predictions. After providing an overview of lithium-ion battery degradation, this paper reviews the current state-of-the-art probabilistic machine learning models for health diagnostics and prognostics. Details of the various methods, their advantages, and limitations are discussed in detail with a primary focus on probabilistic machine learning and uncertainty quantification. Last, future trends and opportunities for research and development are discussed.

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines

The ability of small nucleic acids to modulate gene expression via a range of processes has been widely explored. Compared with conventional treatments, small nucleic acid therapeutics have the potential to achieve long-lasting or even curative effects via gene editing. As a result of recent technological advances, efficient small nucleic acid delivery for therapeutic and biomedical applications has been achieved, accelerating their clinical translation. Here, we review the increasing number of small nucleic acid therapeutic classes and the most common chemical modifications and delivery platforms. We also discuss the key advances in the design, development and therapeutic application of each delivery platform. Furthermore, this review presents comprehensive profiles of currently approved small nucleic acid drugs, including 11 antisense oligonucleotides (ASOs), 2 aptamers and 6 siRNA drugs, summarizing their modifications, disease-specific mechanisms of action and delivery strategies. Other candidates whose clinical trial status has been recorded and updated are also discussed. We also consider strategic issues such as important safety considerations, novel vectors and hurdles for translating academic breakthroughs to the clinic. Small nucleic acid therapeutics have produced favorable results in clinical trials and have the potential to address previously “undruggable” targets, suggesting that they could be useful for guiding the development of additional clinical candidates.

Responses

Your email address will not be published. Required fields are marked *